The Road to Ixtlan in Neuro-Degenerative Diseases Is Paved with Palliative Cobblestones

Abstract

Aday, J. S., C. C. Davoli, and E. K. Bloesch. 2019. 2018: A watershed year for psychedelic science. Drug Science, Policy and Law 5. doi:10.1177/2050324519872284. Chapman, M., J. Philip, and P. Komesaroff. 2019. Towards an ecology of dementia: A manifesto. Journal of Bioethical Inquiry 16 (2):209–16. doi:10.1007/s11673-01909910-8. Cunningham, C., S. Macfarlane, and H. Brodaty. 2019. Language paradigms when behaviour changes with dementia: #BanBPSD. International Journal of Geriatric Psychiatry 34 (8):1109–13. doi:10.1002/gps.5122. Garcia-Romeu, A., S. Darcy, H. Jackson, T. White, and P. Rosenberg. 2022. Psychedelics as novel therapeutics in Alzheimer’s disease: Rationale and potential mechanisms. In Current Topics in Behavioral Neurosciences, eds. F. S. Barrett and K. H. Preller, vol. 56, 287–317. Cham, Switzerland: Springer. Hartogsohn, I. 2021. Set and setting in the Santo Daime. Frontiers in Pharmacology 12:651037. doi:10.3389/fphar. 2021.651037. Noorani, T., and J. Martell. 2021. New frontiers or a bursting bubble? Psychedelic therapy beyond the dichotomy. Frontiers in Psychiatry 12:727050. doi:10.3389/fpsyt.2021. 727050. Norton, M. C., K. W. Piercy, P. V. Rabins, R. C. Green, J. C. Breitner, T. Ostbye, C. Corcoran, K. A. WelshBohmer, C. G. Lyketsos, and J. T. Tschanz. 2009. Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 64 (5):560–8. doi:10.1093/geronb/gbp052. Peterson, A., E. A. Largent, H. F. Lynch, J. Karlawish, and D. Sisti. 2023. Journeying to Ixtlan: Ethics of psychedelic medicine and research for Alzheimer’s disease and related dementias. AJOB Neuroscience 14 (2):107–123. doi: 10.1080/21507740.2022.2148771. Sommerlad, A., S. Sabia, A. Singh-Manoux, G. Lewis, and G. Livingston. 2019. Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study. PLOS Medicine 16 (8): e1002862. doi:10.1371/journal.pmed.1002862. TGA (Therapeutic Goods Administration). 2023. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Accessed February 19, 2023. https://www.tga.gov.au/news/mediareleases/change-classification-psilocybin-and-mdmaenable-prescribing-authorised-psychiatrists.